Outlook Therapeutics, Inc. (OTLK)

NASDAQ

$0.52

$-0.00

(-0.77%)

Pre-Market

Outlook Therapeutics, Inc. (OTLK) Live Price Chart

Last updated: ⁦2026-10-27 13:08:00⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.52, with a market capitalization of $126.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $2.54. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$126.42M
Open	$0.52
Day's High	$219.20
Day's Low	$0.16
Previous Close	$0.51
Volume	7.10K
Average Volume	10.83M
P/E Ratio	--
52-Week High	$2.54
52-Week Low	$0.16
Dividend Yield	--
Earnings Date	--

Outlook Therapeutics, Inc. (OTLK) Pre-Market Stock Price

Outlook Therapeutics, Inc. (OTLK) is trading at $0.52 in pre-market trading as of 2026-10-27 12:55:00, up 0.33% ($0.00) from the previous close of $0.51

Pre-market trading shows how investors are pricing OTLK before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.

Outlook Therapeutics, Inc. (OTLK) 7-Day Stock Price Change

Over the past seven days, Outlook Therapeutics, Inc. (OTLK) moved from $0.49 to $0.52, representing a gain of 5.49% ($0.03).

The stock traded between $0.48 and $0.60 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.

The average daily volume was 3.15 million shares, down versus the previous seven-day period, indicating lower trading activity.

OTLK 52-Week Price Position

Position in Range: 14.9%

52W Low$0.16

52W High$2.54

OTLK is currently trading at $0.52, placing it 14.9% of the way from its 52-week low of $0.16 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Outlook Therapeutics, Inc. (OTLK)?

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	17
Exchange	NASDAQ
Company Website	https://www.outlooktherapeutics.com

How to Buy Outlook Therapeutics, Inc. (OTLK) Stock on MEXC

Eligible investors can buy real shares of Outlook Therapeutics, Inc. (OTLK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for OTLK and Place Your Order

Open the RealStocks trading page and search for OTLK. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Outlook Therapeutics, Inc. (OTLK) stock price today?

Outlook Therapeutics, Inc. (OTLK) is currently trading at $ 0.52, up 0.33% ($0.00) from the previous close of $ 0.51. Intraday prices update in real time during regular trading hours.

2.Is OTLK stock going up or down today?

As of 2026-10-27 12:55:00, OTLK is trading at $ 0.52, up 0.33% ($0.00) from its previous close of $ 0.51. The stock has traded between $ 0.16 and $ 219.20 during today’s regular session. Past price movements do not guarantee future results.

3.What is OTLK pre-market price?

As of 2026-10-27 12:55:00, OTLK is trading at $ 0.52 in pre-market trading, up 0.33% ($0.00) from the previous close of $ 0.51. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is OTLK after-hours price?

As of 2026-10-27 12:55:00, OTLK is trading at $ 0.52 in after-hours trading, up 1.31% ($0.01) from the regular-session close of $ 0.51. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is OTLK stock trading now?

OTLK trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does OTLK sit relative to its 52-week high and low?

Over the past 52 weeks, OTLK has traded between a low of $ 0.16 and a high of $ 2.54. At $ 0.52, the stock is positioned 14.9% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Outlook Therapeutics, Inc. in?

Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Outlook Therapeutics, Inc.'s market capitalization and where is it listed?

Outlook Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 126.42M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is OTLK valued in terms of P/E ratio and EPS?

OTLK trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0.20. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Outlook Therapeutics, Inc. pay a dividend?

Outlook Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.